

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005381

International filing date: 18 February 2005 (18.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 10/783,699  
Filing date: 20 February 2004 (20.02.2004)

Date of receipt at the International Bureau: 23 March 2005 (23.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1296894

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 16, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 10/783,699**

**FILING DATE: February 20, 2004**

**RELATED PCT APPLICATION NUMBER: PCT/US05/05381**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

022004

15992 U.S. PTO

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket No. 54341-0211 (297751)	
(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))		Inventors	Yves Claude Nicolau and Alexey Eliseev
		Title	Methods and Compositions Comprising Non-Peptide Small Molecules That Solubilize the Alzheimer's A $\beta$ Peptide Fiber
		Express Mail Label No.	EV 334684055 US
APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		ADDRESS TO: Commissioner for Patents Mailstop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450	
<p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages <input ]<br="" type="text" value="10"/><i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none"><li>- Descriptive title of the Invention</li><li>- Cross Reference to Related Applications</li><li>- Statement Regarding Fed sponsored R &amp; D</li><li>- Reference to sequence listing, a table, or a computer program listing appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <input ]<="" p="" type="text" value="5"/><p>5. Oath or Declaration [Total Pages <input ]<="" p="" type="text" value="1"/><p>a. <input type="checkbox"/> Newly executed (original or copy)</p><p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) <i>(for a continuation/divisional with Box 18 completed)</i></p><p>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p><p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p></p></p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (<i>if applicable, all necessary</i>)</p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input type="checkbox"/> paper</p> <p>c. <input type="checkbox"/> Statements verifying identity of above copies</p> <p><b>ACCOMPANYING APPLICATIONS PARTS</b></p> <p>9. <input type="checkbox"/> Assignment:</p> <p>a. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>b. <input type="checkbox"/> Assignment is of record in parent application No.</p> <p>10. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement (<i>when there is an assignee</i>) <input type="checkbox"/> Power of Attorney</p> <p>11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)</p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input type="checkbox"/> Other _____</p>	
<p>18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: ____/</p> <p>Prior application information: Examiner ____ Group / Art Unit: ____</p> <p>Recite complete dependency back to first parent application: This application claims priority to U.S. Provisional Patent application serial no. 60/446,840, filed February 12, 2003 and U.S. Provisional Patent application serial no. 60/489,732, filed on July 24, 2003.</p> <p>For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.</p>			
<b>17. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number 23370			
Name (Print/Type)	Sima Singadia Kulkarni	Registration No. (Attorney/Agent)	43,732
Signature	<i>Sima Singadia Kulkarni</i>	Date	February 20, 2004

17497 U.S. PTO  
10/783699

022004

5                                   METHODS AND COMPOSITIONS  
COMPRISING NON-PEPTIDE SMALL MOLECULES THAT  
SOLUBILIZE THE ALZHEIMER'S A $\beta$  PEPTIDE FIBER

10                   FIELD OF THE INVENTION

15                   The present invention is related to methods and compositions for treating Alzheimer's disease. In particular, the present invention comprises novel compositions and methods for destroying the formation of plaques formed via aggregation of fibers of amyloid peptide in its beta sheet conformation (A $\beta$ ).

20                   BACKGROUND OF THE INVENTION

25                   Alzheimer's disease (AD) is a progressive disease of the brain that is characterized by impairment of memory and a disturbance in at least one other thinking function (for example, language or perception of reality). Scientific evidence demonstrates that AD results from an increase in the production or accumulation of a specific protein (beta-amyloid protein) that leads to nerve cell death. Loss of nerve cells in strategic brain areas, in turn, causes deficits in the neurotransmitters, which are the brain's chemical messengers.

30                   Alzheimer's disease is not a normal part of aging and is not something that inevitably happens in later life. Rather, it is one of the dementing disorders, which are a group of brain diseases that result in the loss of mental and physical functions.

35                   The main risk factor for AD is increased age. As the population ages, the frequency of AD continues to increase. 10 % of people over age 65 and 50 % of those over 85 have AD. The number of individuals with AD is expected to be 14 million by the year 2050. In 1998, the annual cost for the care of patients with AD in the United States was approximately \$40,000 per patient.

There are also genetic risk factors for AD. The presence of several family members with AD has suggested that, in some cases, heredity may influence the development of AD. A genetic basis has been identified through the discovery of mutations in several genes that cause AD in a small subgroup of families in which the disease has frequently occurred at relatively early ages (beginning before age 50). Some evidence points to chromosome 19 as implicated in certain other families in which the disease has frequently developed at later ages.

Studies of aging and dementia (general mental deterioration) in the general population have identified three groups of subjects; persons who are not demented, those who are demented, and individuals who cannot be classified because they have a cognitive (thinking, memory) impairment, but do not meet the criteria for dementia.

With the exception of rare cases of familial AD, in whom the disease is caused by mutations (changes in the DNA) of a single gene, most cases of AD are probably caused by a variety of factors acting together. Cases without a family history are called "sporadic." The study of familial AD, however, has uncovered several proteins that are not only important for familial, but also for sporadic AD. These are the amyloid precursor protein (APP) and two presenilins. APP is a major component of plaques (abnormal deposits of proteins in the brain).

The break-down (faulty cleavage) of APPs likely increases their propensity to combine (aggregate) in plaques. Presenilins, on the other hand, are involved in the splitting (cleavage) of APP. Mutations in the genes that encode APPs and the presenilins can cause AD. This means that individuals carrying these mutations have a very high probability of developing AD.

The management of AD consists of medication-based and non-medication based treatments. Treatments aimed at changing the underlying course of the disease (delaying or reversing the progression) have so far been largely unsuccessful. Medicines that restore the deficit (defect), or malfunctioning, in the chemical messengers of the nerve cells (neurotransmitters), such as the cholinesterase inhibitors, have been shown to improve symptoms.

Finally, medications are available that deal with the psychiatric manifestations of AD.

ChEIs are the only agents that are approved by the FDA for the treatment of AD. ChEIs are medicines that restore the defect, or malfunctioning, in the chemical messengers of the nerve cells. These chemical messengers are referred to as neurotransmitters. ChEIs impede the action of an enzyme that inactivates the chemical messengers. Therefore, in the presence of ChEI medicines, more chemical messengers are available to transmit the messages of the nerves in the brain. Although significant treatment effects have been demonstrated indicating that this class of agents is consistently better than a placebo, the disease continues to progress despite treatment, and the average effect on mental functioning has only been modest.

In addition, ChEIs have effects on many aspects of daily living. The principal side effects of ChEIs involve the gastrointestinal system and include nausea, vomiting, cramping, and diarrhea. Tacrine (one of the approved ChEIs) is the only agent that is associated with liver toxicity and the use of this agent requires close hematologic (blood test) monitoring, including liver function tests every other week during the period of dose escalation and every 3 months thereafter. Rivastigmine (another of the approved ChEIs) has been associated with weight loss and the monitoring of the patient's weight is recommended when using this drug.

The occurrence of side effects for ChEIs is related to the rate of dose increase. Therefore, doctors gradually increase the dose at intervals until the optimal therapeutic dosage has been reached. The interval between dose increases may be extended or the dose step size may be reduced accordingly if side effects occur. Between 75% and 90% of patients will tolerate therapeutic doses of ChEIs.

Advances in the understanding of the brain abnormalities that occur in AD are hoped to provide the framework for new targets of treatment that are more focused on altering the course and development of the disease. Many compounds, including anti-inflammatory agents, are being actively investigated. Clinical trials

using specific cyclooxygenase inhibitors (COX-2), such as rofecoxib and celecoxib, are underway.

What is needed therefore, are effective compositions and methods for addressing the complications associated with Alzheimer's disease. In particular what is need are novel pharmaceuticals capable of counteracting the physiological manifestations of the disease such as the formation plaques associated with aggregation of fibers of the amyloid peptide in its beta sheet conformation (A $\beta$ ).

## SUMMARY OF THE INVENTION

The present invention is directed to novel compositions and methods for the treatment of Alzheimer's disease. In particular, the present invention is directed to A $\beta$  fiber solubilization, which is considered to be an approach for the treatment of Alzheimer's disease, and is described herein as being achieved by using small molecules of non-peptide nature. Several classes of compounds are described herein that, according to computer-aided design, are able to provide such a solubilization effect. Also described are methods for designing and testing such molecules for their *in vitro* and *in vivo* activity.

Accordingly, an object of the present invention is to provide novel compositions and methods for the treatment of Alzheimer's disease.

Another object of the present invention is to provide novel compositions and methods for the treatment of Alzheimer's disease comprising small non-peptide molecules that solubilize Alzheimer's A $\beta$  peptide fiber.

Another object of the present invention is to provide methods and compositions for reducing and preventing the formation plaques associated with associated with aggregation of fibers of the amyloid peptide in its beta sheet conformation (A $\beta$ ).

Yet another object of the present invention is to provide the novel compositions that may be administered intramuscularly, intravenously, transdermally, orally, or subcutaneously.

These and other objects, features and advantages of the present invention will become apparent after a review of the

following detailed description of the disclosed embodiment and the appended claims.

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides a schematic showing a chemical approach to combinatorial discovery of  $\beta$ -sheet breaking small molecules.

Figure 2 provides a schematic showing the “morphomer” concept.

Figure 3 provides a schematic showing molecular adaptation of morphomers to the target leading to the formation of strong complexes.

Figure 4 provides a general strategy of small molecules- $\beta$ -sheet breakers for therapy of Alzheimer’s disease.

Figure 5 provides a schematic for screening of small molecules for A $\beta$  solubilization activity.

## DETAILED DESCRIPTION

This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

According to the current understanding, ' development of the Alzheimer's disease is directly related to the formation of plaques formed via aggregation of fibers of the amyloid peptide in its beta-sheet conformation (A $\beta$ ). Therefore, any agent capable of directly destroying the plaques, either via solubilization of A $\beta$  or via its chemical decomposition, is potentially interesting for the Alzheimer's disease therapy.

The  $\beta$ -sheet fiber form of A $\beta$  is formed through a slow conformational change from its soluble form, which is a combination of the  $\alpha$ -helical and random coil structures, followed by aggregation.<sup>2</sup> Thus, one possible mechanism for solubilization of plaques is via thermodynamic stabilization of the soluble form and thereby reversing the fiber precipitation equilibrium. This



concept, referred to as  $\beta$ -sheet breaking, has recently proven successful with a number of P-sheet breaking peptides.<sup>3,4</sup> The low-molecular-weight peptides, primarily fragments or analogs of the native A $\beta$ , were shown to solubilize the A $\beta$  fiber, supposedly by forming a non-covalent complex with the soluble conformation of A $\beta$ . Such an activity of the  $\beta$ -sheet breaking peptides resulted not only in the *in vitro* solubilization of the fiber, but also in the *in vivo* reduction of plaques in mice.

We claim here that the effect of A $\beta$  fiber solubilization, which may eventually prove to be an approach to the treatment of Alzheimer's disease, can be achieved by using small molecules of non-peptide nature. We describe a number of classes of compounds that, according to computer-aided design, are able to provide such a solubilization effect. We also describe the method for designing and testing such molecules for their *in vitro* and *in vivo* activity.

The small molecules described herein are generated from combinatorial libraries of compounds based on the scaffold structures 1-3 or similar compounds that can form non-covalent complexes with the soluble form of A $\beta$ . As shown in Figure 1, the binding of the compounds to A $\beta$  is achieved via combination of electrostatic, hydrophobic, hydrogen-bonding and other kinds of non-covalent interactions with the A $\beta$   $\alpha$ -helical form. The scaffold structures 1-3 have been designed with the aid of computer-assisted molecular modeling, taking into account the projected properties of the library components to facilitate their crossing the blood-brain barrier (BBB).<sup>5,6</sup> The substituents R<sub>1</sub>-R<sub>3</sub> and AA<sub>1</sub>, AA<sub>2</sub> are varied within combinatorial libraries of the potential  $\beta$ -sheet breakers and the resulting component show different activity in the solubilization assays described below.

We also claim here a new concept in the design of the entities engaged in the molecular recognition, i.e. in formation of non-covalent complexes with biological targets, as depicted in pages 4-5.<sup>7</sup> Such entities, defined as morphomers, include a number of bonds, around which the intramolecular rotation is slower than around average single bonds, such as e.g. sp<sup>3</sup> carbon-carbon bond. Although the conformational change occurs in solution, it is sufficiently slow so that corresponding conformers can be observed, for example, as individual peaks in the NMR

spectrum of the compounds. The examples of such conformationally restricted bonds are shown with arrows in structures 1-3. The different conformational states of these compounds, named morphomers, therefore form a sub-library of the main combinatorial library. Two properties of the morphomers are important for pharmaceutical applications: (i) binding energy to the target differs from one morphomer to the other; (ii) binding energy of a morphomer that has a better geometrical and functional fit to the target is higher than that of a similar compound with unrestricted conformations, as shown in Figure 3.

A general strategy for the discovery of small molecule-  $\beta$ -sheet breakers is shown in Figure 4. It consists of computer-aided design of the molecular scaffolds, their synthesis, formation of the combinatorial libraries, and their screening *in vitro* and *in vivo* using known procedures. The *in vitro* assay is performed with either thioflavin T staining assay or by direct detection of A $\beta$  complexes with library members by mass spectrometry. The *in vivo* assay has been recently published (ref. Figure 5)

## References

- (1) Soto, C. *Mol. Med. Today* 1999, 5, 343-350.
- (2) Jarvet, J.; Damberg, P.; Bodell, K.; Eriksson, L. E. G.; Graslund, A. J. *Am. Chem. Soc.* 2000, 122, 4261-4268.
- 5     $\beta$ ) Poduslo, J. F.; Curran, G. L.; Kumar, A.; Frangione, B.; Soto, C. J. *Neurobiol* 1999, 39, 371-382.
- (4) Sigurdsson, E. M.; Permanne, B.; Soto, C.; Wisniewski, T.; Frangione, B. J. *Neuropathol. Exp. Neurol* 2000, 59, 11-17.
- 10    (5) Begley, D. J. *Journal of Pharmacy & Pharmacology* 1996, 48, 136-146.
- (6) Cecchelli, R.; Dehouck, B.; Descamps, L.; Fenart, L.; Buee-Scherrer, V.; Duhem, C.; Lundquist, S.; Rentfel, M.; Torpier, G.; Dehouck, M. P. *Adv. Drug Deliv. Rev* 1999, 36, 165-178.
- 15    (7) Bunyapaiboonsri, T.; Lehn, J.-M. unpublished work.

## CLAIMS

We claim:

- 5        1.     A composition comprising small molecules for breaking of  $\beta$ -sheet conformation in amyloid protein.

METHODS AND COMPOSITIONS  
COMPRISING NON-PEPTIDE SMALL MOLECULES THAT  
SOLUBILIZE THE ALZHEIMER'S A $\beta$  PEPTIDE FIBER

5

ABSTRACT OF THE INVENTION

10 The present invention comprises novel compositions and  
methods for the treatment of Alzheimer's disease. In particular, the  
present invention is directed to A $\beta$  fiber solubilization, for the  
treatment of Alzheimer's disease, and is described herein as being  
achieved by using small molecules of non-peptide nature.

15

54341-0211 (297751)

20

# Chemical Approach to Combinatorial Discovery Of $\beta$ -sheet-Breaking Small Molecules

1  
2  
3




- 1 – Helix stabilization by selective electrostatic interactions
- 2 – Helix stabilization via interaction with the rigid hydrophobic scaffold
- 3 – Combinatorially varied substituents

Figure 1

BEST AVAILABLE COPY

## “Morphomer” concept



- Molecular scaffolds are designed complementary to A $\beta$  helical (soluble) structure
- Conformational restrictions are introduced to partially lock each set of conformations (*morphology*) of library components
- Libraries formed on the basis of scaffolds explore both chemical (Rx) and conformational diversity space

Figure 2

# Molecular Adaptation of Morphomers to the Target Leads to Formation of Stronger Complexes





Figure 3



# General Strategy of Small Molecules – $\beta$ -Sheet breakers for Therapy of Alzheimer's Disease

Bioavailability:  
focused design of components  
capable of crossing BBB




## 1. Design:

Libraries of small molecules –  
 $\beta$ -sheet breakers

Proprietary  
structural design

Morphomer  
concept

Scaffold synthesis



## 2. Library generation

*In vitro*

Fluorescent A $\beta$   
solubilization assay  
+ analysis of hits  
by mass spectrometry

*In vivo* HTS

$\beta$ -Galactosidase  
complementation  
assay

## 3. Screening

Know-how

Figure 4

# Screening of Small Molecules for A $\beta$ Solubilization Activity

## *In vitro*

- **Fluorescent Assay:**


A $\beta$  fiber stained with Thioflavin T solubilization/depolymerization is monitored by fluorescence decrease

- **Mass spectrometry assay:**

Complexes of amyloid with small molecules are detected and characterized by MS

Hits are fully structurally characterized using regiochemical tagging techniques (*provisional patent application filed*)

## *In vivo*



*in vivo* solubilization assay for A $\beta$   
(W.C. Wigley, et al.  
*Nature Biotechnol.* 2001, 19, 131-136)

**Figure 5**